The Prevalence of Premonitory Symptoms in Migraine: A Questionnaire Study in 461 Patients

Schoonman, GG; Evers, D.J.; Terwindt, GM; Dijk, J.J.M. van; Ferrari, Michel D.

doi:10.1111/j.1468-2982.2006.01195.x

Cited by 165 publications

(173 citation statements)

References 13 publications

Supporting

Mentioning

145

Contrasting

Unclassified

Order By: Relevance

“…[8][9][10][11][12][13] In addition, the majority of the studies performed so far have only looked at symptoms starting before the…”

Section: Prevalence Of Premonitory-like Symptoms In Migrainementioning

confidence: 99%

“…[8][9][10][11][12][13] In addition, the majority of the studies performed so far have only looked at symptoms starting before the prevalence rates of 9-88%. 3,[8][9][10][11][12][13][14][15][16][17][18] See Table 1 for a breakdown of studies to date in the literature looking at premonitory symptom prevalence.…”

Section: Prevalence Of Premonitory-like Symptoms In Migrainementioning

confidence: 99%

“…[9][10][11][12][13][14][15][16] The most common symptoms seem to be fatigue (see red in Table 1), mood change (see blue in Table 1) and yawning (see green in Table 1). These are consistent across the studies.…”

Section: Phenotype Of Premonitory-like Symptomsmentioning

confidence: 99%

See 2 more Smart Citations

Premonitory-like Symptomatology in Migraine

Karsan

Goadsby²

2017

European Neurological Review

View full text Add to dashboard Cite

It has been historically accepted that migraine involves symptomatology outside of head pain. These symptoms can be as equally disabling as the pain, and can include tiredness, concentration impairment, memory impairment and mood change. The symptoms may start before the onset of pain and can persist throughout the headache phase, and even after effective headache treatment into the postdrome. Despite knowledge of these symptoms, their neurobiologic basis and relationship to migraine pain is poorly understood. The fact that these symptoms start early, up to hours to days before the onset of headache, and are so symptomatically heterogeneous, suggests that the neurobiology of migraine extends beyond conventionally accepted anatomical pain areas within the brain -what has been known as the pain matrix or network. In a research area where no effective acute abortive drugs have gained a license for migraine since the triptans (serotonin 5-HT 1B/1D receptor agonists), in the 1990s, further understanding of such symptomatology will allow therapeutic advances for treatments that may work before the onset of migraine pain and thus prevent it. This review will outline our current understanding about the phenotype and neurobiology of the premonitory (prodromal) symptoms, which for the purpose of this review will be called 'premonitorylike', given they can start before or during pain. Symptoms starting after pain resolution (postdromal symptoms) will not be covered here. KeywordsMigraine, premonitory, prodrome, functional imaging Disclosure: Nazia Karsan is an Association of British Neurologists/Guarantors of Brain Clinical Research Training Fellow. Peter J Goadsby reports personal fees from Allergan, Amgen, and Eli-Lilly and Company; and personal fees from Akita Biomedical, Alder Biopharmaceuticals, Autonomic Technologies Inc., Avanir Pharma, Cipla Ltd, CoLucid Pharmaceuticals Inc., Dr Reddy's Laboratories, eNeura, ElectroCore LLC, Novartis, Pfizer Inc., Promius Pharma, Quest Diagnostics, Scion, Teva Pharmaceuticals, Trigemina Inc., Scion; and personal fees from MedicoLegal work, Journal Watch, Up-to-Date, Oxford University Press; in addition, Peter J Goadsby has a magnetic stimulation for headache patent pending assigned to eNeura. No funding was received for the publication of this article. Peter J Goadsby is a member of the European Neurological Review Editorial Board. Compliance with Ethics:This study involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.Authorship: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole and have given final approval for the version to be published.Open Access: This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation, and reproduction provided the original author(s) and source are giv...

show abstract

“…[8][9][10][11][12][13] In addition, the majority of the studies performed so far have only looked at symptoms starting before the…”

Section: Prevalence Of Premonitory-like Symptoms In Migrainementioning

confidence: 99%

Section: Prevalence Of Premonitory-like Symptoms In Migrainementioning

confidence: 99%

See 1 more Smart Citation

Premonitory-like Symptomatology in Migraine

Karsan

Goadsby²

2017

European Neurological Review

View full text Add to dashboard Cite

show abstract

“…The most frequently reported premonitory symptoms are fatigue, phonophobia, and yawning (Schoonman et al 2006). Concerning trigger factors, the most common ones are stress, the perimenstrual period, and alcohol (Karli et al 2005).…”

Section: Phenotypementioning

confidence: 99%

Current migraine management – patient acceptability and future approaches

Fumal

Schoenen

2008

NDT

View full text Add to dashboard Cite

Despite its high prevalence and individual as well as societal burden, migraine remains underdiagnosed and undertreated. In recent years, the options for the management of migraine patients have greatly expanded. A number of drugs belonging to various pharmacological classes and deliverable by several routes are now available both for the acute and the preventive treatments of migraine. Nevertheless, disability and satisfaction remain low in many subjects because treatments are not accessible, not optimized, not effective, or simply not tolerated. There is thus still considerable room for better education, for more effi cient therapies and for greater support from national health systems. In spite of useful internationally accepted guidelines, anti-migraine treatment has to be individually tailored to each patient taking into account the migraine subtype, the ensuing disability, the patient's previous history and present expectations, and the co-morbid disorders. In this article we will summarize the phenotypic presentations of migraine and review recommendations for acute and preventive treatment, highlighting recent advances which are relevant for clinical practice in terms of both diagnosis and management.

show abstract

“…85 Some reports show that cervical pain and stiffness may be premonitory (up to 35% of crisis), may trigger, and/or be additional to an episode of migraine. [85][86][87] In a survey of a group of teenagers, 63% of the group of migraine patients reported cervical and shoulder pain. These cases are twice or three times more common than in patients who do not suffer from migraine.…”

mentioning

confidence: 99%